Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc. (DAWN) Revenue
Annual & quarterly revenue history · segment & region breakdown
DAWN · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsDay One Biopharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.16B, an increase of 20.60% year-over-year from $0.16B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.16B | +$0.03B | +20.60% |
| 2024-12-31 | $0.13B | +$0.13B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare DAWN revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Day One Biopharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Day One Biopharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Day One Biopharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
DAWN revenue · 4 questionsDAWN's trailing twelve-month (TTM) revenue is $0.16B. That is an increase of 20.60% year-over-year from $0.16B in FY2025.
▸ Source: FMP · Day One Biopharmaceuticals, Inc. SEC filings · GAAP · Day One Biopharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026